CLPTHealthcare · Medical DevicesThe 2 Wall Street analysts covering Clearpoint Neuro, Inc. hold a median 12-month price target of $24 — +124.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Clearpoint Neuro, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (60): Smaller than most of the companies we track.
Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CLPT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +124.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 June 2026 | B. Riley Securities | Maintains | Buy | $20 → $30 |
| 18 Mar 2026 | B. Riley Securities | Maintains | Buy | — |
| 5 Mar 2026 | B. Riley Securities | Maintains | Buy | — |
| 1 Aug 2025 | Stifel | Maintains | Buy | — |
| 25 Apr 2025 | B. Riley Securities | Maintains | Buy | — |
| 1 Apr 2025 | Stifel | Maintains | Buy | — |
| 28 Jan 2025 | B. Riley Securities | Maintains | Buy | — |
| 21 Jan 2025 | Lake Street | Maintains | Buy | — |
| 27 Aug 2024 | Lake Street | Maintains | Buy | — |
| 13 Mar 2024 | Stifel | Reiterates | Buy | — |
| 24 Oct 2023 | Stifel | Initiates | Buy | — |
| 9 Aug 2023 | Lake Street | Maintains | Buy | — |
| 16 Feb 2023 | B. Riley Securities | Reinstates | Buy | $14 |
| 5 Apr 2022 | B. Riley Securities | Reinstates | Buy | $15 |
| 18 Mar 2021 | Lake Street | Initiates | Buy | — |
| 17 July 2020 | B. Riley Securities | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLPT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Clearpoint Neuro, Inc. returned −64.6% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 94% of US stocks
Cheaper than 17% of US stocks
Cheaper than 3% of US stocks
Cheaper than 87% of US stocks
Higher than 67% of US stocks
Higher than 56% of US stocks
Higher than 75% of US stocks
Higher than 14% of US stocks
Higher than 7% of US stocks
Higher than 6% of US stocks
Higher than 17% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Clearpoint Neuro, Inc. has a market value of $335.9M and an enterprise value of $370.4M.
Revenue in the twelve months to 30 June 2026: $42.3M. The latest quarter grew 18.1% year on year.
Net income over the same four quarters: −$34.6M, a −81.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$31.3M.
Trailing P/E: −12.1×; forward P/E: −9.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Clearpoint Neuro, Inc. employs 160 people — $264K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Clearpoint Neuro, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
SBS Law announced an opportunity for ClearPoint Neuro investors with $100,000 in losses to join a fraud investigation.
Why it matters — The announcement concerns a fraud investigation involving CLPT and may be relevant to investors following the company.
Cedar Grove Capital reported that it closed its long position in ClearPoint Neuro during the quarter, alongside long positions in three other companies.
Why it matters — The update indicates Cedar Grove Capital no longer held a long position in CLPT at quarter-end, according to the excerpt.
ClearPoint Neuro reported weak second-quarter results, particularly in drug delivery disposables, and experienced delays in scaling preclinical services at its new facility, lowering expectations for 2026. However, regulatory clarity has improved, making a revenue inflection likely in 2027/2028 as AMT-130 is commercialized.
Why it matters — The article highlights a mixed outlook for CLPT — near-term operational weakness offset by clearer regulatory prospects that could drive meaningful revenue growth in 2027/2028.
ClearPoint Neuro, Inc. held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha.
Why it matters — The earnings call transcript provides investors and analysts with management's discussion of the company's quarterly financial performance and strategic outlook.
ClearPoint Neuro (CLPT) reported its financial results for the quarter ended June 2026. Zacks notes that beyond headline numbers, it may be useful to compare the company's key metrics to Wall Street estimates and year-ago actuals.
Why it matters — CLPT watchers can check how the company's key operational metrics stacked up against analyst expectations and prior-year results for the quarter.
The 2 Wall Street analysts covering Clearpoint Neuro, Inc. have a median 12-month price target of $24, with estimates ranging from $22 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Clearpoint Neuro, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Clearpoint Neuro, Inc. 20 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Clearpoint Neuro, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (60 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +124.0% from the last close, and Ticker Nerd's factor model ranks Clearpoint Neuro, Inc. 20 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Clearpoint Neuro, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLPT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $25 over the next 12 months.
Clearpoint Neuro, Inc. returned -64.6% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
ClearPoint Neuro Inc. is a medical technology company focused on precision navigation and delivery solutions for complex neurological procedures.
The most recent item we track (Business Wire, 8 Oct 2026): "CLPT Investors with $100,000 in Losses Have Opportunity to Join ClearPoint Neuro, Inc. Fraud Investigation with SBS Law". SBS Law announced an opportunity for ClearPoint Neuro investors with $100,000 in losses to join a fraud investigation.
ClearPoint Neuro Inc. is a medical technology company focused on precision navigation and delivery solutions for complex neurological procedures. The company develops and commercializes platforms used in minimally invasive brain and spine interventions, combining hardware, disposable instruments, and software that support surgical planning, targeting, and procedure monitoring. Its product portfolio includes MRI-guided navigation systems, laser therapy tools, and therapy-delivery components designed to help clinicians access hard-to-reach areas of the central nervous system with greater control. ClearPoint Neuro also provides enabling services for cell, gene, and drug delivery programs, supporting medical and research partners with preclinical and clinical development workflows. The company serves healthcare and research centers across multiple global regions, making it an important specialist in image-guided neurosurgical technology and therapeutic delivery.
CEO Mr. Joseph Michael Burnett · 160 employees · United States · https://www.clearpointneuro.com
